Document resource
Cardiovascular disease remains the primary cause of mortality among women worldwide.1 Nevertheless, sex-specific evidence still lags compared with that for men only. The majority of our current practice rests on a ‘one-size-fits-all’ approach, developed from studies involving predominantly male cohorts, and subsequently extrapolated to women. The costs of this neglect are substantial in both human and socio-economic terms: the World Economic Forum (WEF), in collaboration with the McKinsey Health Institute, published its 2024 Blueprint to close the women’s health gap and estimated that closing the health gap for women by focusing on only nine conditions could prevent almost 27 million disability-adjusted life years every year.2 Economically, the gains are equally striking; improved health for women could boost global gross domestic product by US$1 trillion per year by 2040. Within cardiovascular health specifically, the potential benefits are evenly substantial as well. In the USA alone, better prevention and management of women’s heart disease could regain at least 1.6 million years of higher quality life (quality-adjusted life year, QALY) and add US$28 billion annually to the economy. This highlights that closing the ‘women’s health gap’ should be both a clinical priority and a socio-economic necessity.